The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects
Al-Qaissi, Ahmed; Alqarni, Saeed; Javed, Zeeshan; Atkin, Stephen L.; Sathyapalan, Thozhukat; Vince, Rebecca; Madden, Leigh A.
Stephen L. Atkin
Professor Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Dr Rebecca Vince Rebecca.Vince@hull.ac.uk
Senior Lecturer in Health Physiology
Dr Leigh Madden L.A.Madden@hull.ac.uk
Post-Doctoral Research Assistant
© 2019, The Author(s). Background: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). Methods: In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D, n = 105), women with polycystic ovary syndrome (PCOS, n = 145) and healthy volunteers (n = 69). All data were generated via the same flow cytometry protocol with the same antibody clones. Endothelial markers CD105 (Endoglin) and CD106 (Vascular cell adhesion molecule-1) were used to enumerate MP in venous blood. Results: The ratio of CD105MP:CD106MP was significantly different between groups (F = 63.43, p < 0.0001). Women with PCOS were found to have a median CD105MP:CD106MP ratio of 0.40 (IQR 0.24–0.57), suggesting approximately two CD106MP were found per CD105MP. The T2D group showed a median ratio of 2.32 (1.51–3.69) whereas in healthy volunteers the ratio was 2.21 (1.63–3.55). Serum intercellular adhesion molecule-1 was also shown to be significantly increased in PCOS when compared with control or T2D groups (F = 14.5, p < 0.001). Conclusion: These data suggest that women with PCOS have an altered endothelial MP release in favour of CD106. Thus a potential activated endothelial state exists in women with PCOS with a shift towards a predominantly CD106MP profile.
Al-Qaissi, A., Alqarni, S., Javed, Z., Atkin, S. L., Sathyapalan, T., Vince, R., & Madden, L. A. (2019). The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects. Endocrine, https://doi.org/10.1007/s12020-019-02059-9
|Journal Article Type||Article|
|Acceptance Date||Aug 12, 2019|
|Online Publication Date||Aug 27, 2019|
|Publication Date||Aug 27, 2019|
|Deposit Date||Aug 31, 2019|
|Publicly Available Date||Oct 27, 2022|
|Publisher||Springer (part of Springer Nature)|
|Peer Reviewed||Peer Reviewed|
|Keywords||Polycystic ovary syndrome; Endothelial microparticles; VCAM-1|
© The Author(s) 2019<br /> Open Access<br /> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.